Complete Pharmacovigilance Solutions Limited - Period Ending 2018-12-31

Complete Pharmacovigilance Solutions Limited - Period Ending 2018-12-31


Complete Pharmacovigilance Solutions Limited 09369371 false 2018-01-01 2018-12-31 2018-12-31 The principal activity of the company is that of the provision of covigilance solutions to the pharmaceutical industry. Digita Accounts Production Advanced 6.24.8820.0 Software true 09369371 2018-01-01 2018-12-31 09369371 2018-12-31 09369371 bus:Director1 1 2018-12-31 09369371 core:CurrentFinancialInstruments core:WithinOneYear 2018-12-31 09369371 bus:Micro-entities 2018-01-01 2018-12-31 09369371 bus:AuditExemptWithAccountantsReport 2018-01-01 2018-12-31 09369371 bus:FullAccounts 2018-01-01 2018-12-31 09369371 bus:SmallCompaniesRegimeForAccounts 2018-01-01 2018-12-31 09369371 bus:RegisteredOffice 2018-01-01 2018-12-31 09369371 bus:Director1 2018-01-01 2018-12-31 09369371 bus:Director1 1 2018-01-01 2018-12-31 09369371 bus:PrivateLimitedCompanyLtd 2018-01-01 2018-12-31 09369371 countries:AllCountries 2018-01-01 2018-12-31 09369371 2017-01-01 2017-12-31 09369371 2017-12-31 09369371 bus:Director1 1 2017-12-31 09369371 core:CurrentFinancialInstruments core:WithinOneYear 2017-12-31 09369371 bus:Director1 1 2017-01-01 2017-12-31 iso4217:GBP xbrli:pure

Registration number: 09369371

Complete Pharmacovigilance Solutions Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2018

 

Complete Pharmacovigilance Solutions Limited

(Registration number: 09369371)
Balance Sheet as at 31 December 2018

2018
£

2017
£

Fixed assets

389,263

3,081

Current assets

395,101

488,219

Creditors: Amounts falling due within one year

(135,069)

(25,704)

Net current assets

260,032

462,515

Total assets less current liabilities

649,295

465,596

Accruals and deferred income

(1,500)

(1,250)

 

647,795

464,346

Capital and reserves

647,795

464,346

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
The Old Workshop
12B Kennerleys Lane
Wilmslow
Cheshire
SK9 5EQ
England

These financial statements were authorised for issue by the Board on 3 September 2019.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2017 - 3).

3

Related party transactions

Transactions with directors

2018

At 1 January 2018
£

Advances to directors
£

Repayments by director
£

At 31 December 2018
£

Dr Irfan Ahmad

Interest is charged at 3% per annum and is payable half -yearly. The loan is repayable on demand.

300,120

290,000

(266,000)

324,120

         
       

 
 

Complete Pharmacovigilance Solutions Limited

(Registration number: 09369371)
Balance Sheet as at 31 December 2018

2017

At 1 January 2017
£

Advances to directors
£

Repayments by director
£

At 31 December 2017
£

Dr Irfan Ahmad

Interest is charged at 3% per annum and is payable half -yearly. The loan is repayable on demand.

274,120

290,000

(264,000)

300,120

         
       

 

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

For the financial year ending 31 December 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the Board on 3 September 2019 and signed on its behalf by:
 

.........................................

Dr Irfan Ahmad
Director